Association between metformin prescription and growth rates of abdominal aortic aneurysms

J. Golledge, J. Moxon, J. Pinchbeck, G. Anderson, S. Rowbotham, J. Jenkins, M. Bourke, B. Bourke, A. Dear, T. Buckenham, R. Jones, P. E. Norman

    Research output: Contribution to journalArticlepeer-review

    60 Citations (Scopus)


    Background: It has been suggested that diabetes medications, such as metformin, may have effects that inhibit abdominal aortic aneurysm (AAA) growth. The aim of this study was to examine the association of diabetes treatments with AAA growth in three patient cohorts. Methods: AAA growth was studied using ultrasound surveillance in cohort 1, repeated CT in cohort 2 and more detailed repeat CT in cohort 3. Growth was estimated by the mean annual increase in maximum AAA diameter. Results: A total of 1697 patients with an AAA were studied, of whom 118, 39 and 16 patients were prescribed metformin for the treatment of diabetes in cohorts 1, 2 and 3 respectively. Prescription of metformin was associated with a reduced likelihood of median or greater AAA growth in all three cohorts (cohort 1: adjusted odds ratio (OR) 0·59, 95 per cent c.i. 0·39 to 0·87, P = 0·008; cohort 2: adjusted OR 0·38, 0·18 to 0·80, P = 0·011; cohort 3: adjusted OR 0·13, 0·03 to 0·61, P = 0·010). No other diabetes treatment was significantly associated with AAA growth in any cohort. Conclusion: These findings suggest a potential role for metformin in limiting AAA growth.

    Original languageEnglish
    Pages (from-to)1486-1493
    Number of pages8
    JournalBritish Journal of Surgery
    Issue number11
    Publication statusPublished - 1 Oct 2017


    Dive into the research topics of 'Association between metformin prescription and growth rates of abdominal aortic aneurysms'. Together they form a unique fingerprint.

    Cite this